Calculating the Prevalence of Urea Cycle Disorders in the EU5 Using an Incidence-Survival Model
Gilan Megeed, MPH
Deerfield Institute, New York, NY

Background
- Therapies for rare diseases have ignited industry-wide debates concerning patient access, pricing and efficacy. Urea cycle disorders (UCD), a genetic rare disease, is a target for enzyme replacement therapies, yet UCD epidemiology data are scarce. For payers and pharmaceutical companies to accurately forecast patient cost of care, accurate patient population estimates are a necessity.

Objectives
- The objective of this study is to estimate the prevalence of UCD in the 0–17 year-old population in five major European markets (EU5) (France, Germany, Italy, Spain, UK).

Methods
- We included males and females ages 0-17 years. We excluded patients older than 17 years to remove the mild patients, who may not require therapy, and have a population that better represents severe patients requiring chronic, expensive treatment.
- We designed an incidence-survival model utilizing birth incidence, annual life-expectancy and country-specific newborn data. Birth incidence estimates for UCD were obtained from the Urea Cycle Disorders Consortium (UCDC).
- We conducted a literature review to determine the annual life expectancy of UCD.
- Finally, we reviewed available EUS newborn census data to obtain the number of newborns in each country from 2001 to 2012. We extrapolated the trend from 2001-2012 to forecast the number of newborns through 2024. These data were entered into the incidence-survival model to calculate the prevalence of UCD from 2015-2024.

Results
- We estimated a prevalence of 1.71 per 100,000 population in the 0–17 year age groups resulting in 1,027 and 1,033 UCD cases in the EU5 in 2015 and 2024, respectively.
- The prevalence was 1.89 per 100,000 in the 0-4 year-old age group, 1.63 per 100,000 in the 10-14 year-old age group, and 1.57 per 100,000 in 15-17 year-old age group.
- The survival of UCD decreased considerably over the first 10 years of life, from a 73% survival at age 1 year to a 58% survival at age 10 years.
- The five most frequent subtypes of UCD (OTCD, ASLD, ASSD, ARGD) constitute collectively 93.1% of the UCD population. The proportions are 59.9%, 15.5%, 14.2%, 3.5%, respectively.

Conclusions
- To our knowledge, this study provides the first prevalence estimate of UCD in the EU5 markets.
- Incidence–survival models provide an alternative method to estimating prevalent cases when prevalence data are scarce or unreliable.
- With 1,027 estimated cases in 2015, it is expected that UCD treatments will be expensive given the small size of the patient population.
- With low expected survival, treatment options should target the 0-10 years pediatric age group.
- In conclusion, these estimates can be used to approximate the total cost burden of UCD and the resulting cost-effectiveness of UCD treatments.

Table 1: Age Distribution of UCD Patients, Males & Females, 2015

<table>
<thead>
<tr>
<th>Age Groups</th>
<th>Proportion of Patients</th>
<th>Cumulative Patient Proportion</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-3 years</td>
<td>25.01%</td>
<td>25.01%</td>
</tr>
<tr>
<td>4-6 years</td>
<td>17.27%</td>
<td>42.27%</td>
</tr>
<tr>
<td>7-10 years</td>
<td>21.85%</td>
<td>64.12%</td>
</tr>
<tr>
<td>11-13 years</td>
<td>15.52%</td>
<td>79.64%</td>
</tr>
<tr>
<td>14-17 years</td>
<td>20.36%</td>
<td>100.00%</td>
</tr>
</tbody>
</table>

Table 2: Number of Prevalent Cases by Subtype in the EU5 in 2015

<table>
<thead>
<tr>
<th>Subtype</th>
<th>France</th>
<th>Germany</th>
<th>Italy</th>
<th>Spain</th>
<th>United Kingdom</th>
<th>EUS</th>
</tr>
</thead>
<tbody>
<tr>
<td>OTCD</td>
<td>152</td>
<td>131</td>
<td>105</td>
<td>90</td>
<td>137</td>
<td>615</td>
</tr>
<tr>
<td>ASLD</td>
<td>39</td>
<td>34</td>
<td>27</td>
<td>23</td>
<td>35</td>
<td>159</td>
</tr>
<tr>
<td>ASSD</td>
<td>36</td>
<td>31</td>
<td>25</td>
<td>21</td>
<td>32</td>
<td>146</td>
</tr>
<tr>
<td>ARGD</td>
<td>9</td>
<td>8</td>
<td>6</td>
<td>5</td>
<td>8</td>
<td>36</td>
</tr>
</tbody>
</table>

Contact Information:
Gilan Megeed
Deerfield Institute
780 Third Avenue, 37th floor
New York, NY 10017
gmegeed@deerfield.com

References:
1. Batshaw et al. Mol Gen and Metab. 2014; 113: 127-130

Presented at the 18th Annual Congress of the International Society for Pharmacoeconomics and Outcomes Research
7-11 November 2015
Milan, Italy